Centene said premium and service revenues for Q1 2025 were $42.5 billion, representing 17% growth year-over-year, diluted EPS was $2.63 compared to $2.16 in the prior-year quarter, and adjusted diluted EPS was $2.90 compared to $2.26 in the prior-year quarter.

10-QQuarterly reportFiled Apr 25, 2025Period of report Mar 31, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

Centene said premium and service revenues for Q1 2025 were $42.5 billion, representing 17% growth year-over-year, diluted EPS was $2.63 compared to $2.16 in the prior-year quarter, and adjusted diluted EPS was $2.90 compared to $2.26 in the prior-year quarter.
The company said the HBR for Q1 2025 was 87.5%, compared to 87.1% in the prior-year quarter, and cited influenza-and-like illnesses as a factor in the higher Medicaid HBR. The adjusted SG&A expense ratio was 7.9% compared to 8.7% in the prior-year quarter.
Centene said operating activities provided cash of $1.5 billion for Q1 2025, compared to cash used of $456 million in the prior-year quarter. It said net earnings and an increase in medical claims liabilities contributed to the cash flows, partially offset by a delay in premium payments from one of its state partners.
The company said its debt-to-capital ratio as of March 31, 2025 was 39.5%, lower than 41.2% as of December 31, 2024. It added that the remaining authorization under its share repurchase program was $2.2 billion with no expiration date.

Key figures

Quarter ended March 31, 2025

Operating income: $1.5B
Net income: $1.3B
EPS: $2.63
Gross profit: $5.3B
Operating cash flow: $1.5B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q1 2025 Premium and Service Revenues and EPS

Centene said premium and service revenues for Q1 2025 were $42.5 billion, representing 17% growth year-over-year, diluted EPS was $2.63 compared to $2.16 in the prior-year quarter, and adjusted diluted EPS was $2.90 compared to $2.26 in the prior-year quarter.

Source · Based on the MD&A text of the filing

HBR 87.5% and Adjusted SG&A Expense Ratio 7.9%

The company said the HBR for Q1 2025 was 87.5%, compared to 87.1% in the prior-year quarter, and cited influenza-and-like illnesses as a factor in the higher Medicaid HBR. The adjusted SG&A expense ratio was 7.9% compared to 8.7% in the prior-year quarter.

Source · Based on the MD&A text of the filing

Q1 2025 Operating Cash Flows

Centene said operating activities provided cash of $1.5 billion for Q1 2025, compared to cash used of $456 million in the prior-year quarter. It said net earnings and an increase in medical claims liabilities contributed to the cash flows, partially offset by a delay in premium payments from one of its state partners.

Source · Based on the MD&A text of the filing

Debt-to-Capital Ratio and Share Repurchase Program Remaining Authorization

The company said its debt-to-capital ratio as of March 31, 2025 was 39.5%, lower than 41.2% as of December 31, 2024. It added that the remaining authorization under its share repurchase program was $2.2 billion with no expiration date.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.